BlossomHill Therapeutics, Inc. (BLSM)
Nasdaq · Healthcare · Biotechnology
$19.94+1.27%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $634M
- 52-week range
- $15.25 – $27.99
- 52-week change
- +23.06%
- EPS (trailing)
- −$4.70
- Analyst rating
- 1.2 Strong buy
- Next earnings
- Nov 16, 2026
About BlossomHill Therapeutics, Inc.
BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that address medical needs in cancer treatment. Its pipeline includes BH-30643, an OMNI-EGFR inhibitor in clinical development for advanced EGFR-mutant non-small cell lung cancer (NSCLC), BH-501284, and BH-30236, a macrocyclic CLK (Cdc2-like kinase) inhibitor being evaluated in patients with relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndrome (HR-MDS). BlossomHill Therapeutics, Inc. was incorporated in 2020 and is based in San Diego, California.
Headquarters: San Diego, United States · 69 employees · bhtherapeutics.com